Odyssée Venture

Odyssee Venture is an independent Paris-based private-equity and venture-capital management company founded in 1999, headquartered at 26 rue de Berri in the 8th arrondissement, and one of the earliest AMF-accredited independent asset managers in France. The firm was co-founded by Mathieu Boillet and Sebastien Sassolas, who previously ran the venture-capital activities of the Banques Populaires Group through SPEF — historically France's first institutional venture investor. Over more than 25 years Odyssee has raised over EUR 750 million across FCPI, FIP, and FCPR vehicles and has financed roughly 200 French growth SMEs. Odyssee leads rounds and focuses on growth-stage investments in French SMEs spanning business and consumer products, financial services, healthcare and life sciences, SaaS, manufacturing and industrials, and e-commerce — deploying tickets from EUR 1 million to EUR 10 million with a typical average around EUR 5 million. Across 181 disclosed investments the portfolio includes BrightHeart, a prenatal ultrasound AI company for which Odyssee led an EUR 11 million Series A in January 2026 following five FDA approvals in 2025; Veesion, an AI shoplifting-gesture detection company that raised EUR 38 million to expand into the US; VitaDX, a urine-based cancer diagnostics firm; PeopleSpheres; Ekinops; Scaled Risk; and GymGlish. Odyssee's 25-year track record spans multiple economic cycles and fund formats, giving it an unusually deep bench of relationships across the French growth-company ecosystem. The firm's FCPI and FIP products are distributed to retail investors, making it one of the few French VCs with both institutional and retail LP exposure — a breadth that supports consistent capital formation across market conditions.